Michael B Ward
Overview
Explore the profile of Michael B Ward including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janetzki J, Sykes M, Ward M, Pratt N
Drug Saf
. 2023 Nov;
47(1):59-70.
PMID: 37995048
Background And Objective: Prior molecular modelling analysis identified several medicines as potential inhibitors of glutathione peroxidase 1 (GPx1) which may contribute to development or progression of chronic obstructive pulmonary disease...
2.
Janetzki J, Pratt N, Ward M, Sykes M
Pharm Res
. 2023 May;
40(6):1553-1568.
PMID: 37173537
Background: Chronic Obstructive Pulmonary Disease is characterised by declining lung function and a greater oxidative stress burden due to reduced activity of antioxidant enzymes such as Glutathione Peroxidase 1. Objectives:...
3.
Wong S, Davis A, Selby P, Khoo R, Gwilt I, Stocker S, et al.
Ther Drug Monit
. 2022 Oct;
45(3):368-375.
PMID: 36194490
Background: Different software applications have been developed to support health care professionals in individualized drug dosing. However, their translation into clinical practice is limited, partly because of poor usability and...
4.
Janetzki J, Sykes M, Ward M, Pratt N
J Clin Pharm Ther
. 2021 Aug;
46(6):1687-1694.
PMID: 34431531
What Is Known And Objective: Proton pump inhibitors (PPIs), used to treat and prevent gastro-oesophageal conditions, are well-tolerated but have been associated with risk including pneumonia. The extent to which...
5.
Li J, Mulvihill T, Li L, Barrott J, Nelson M, Wagner L, et al.
Cancer Discov
. 2021 Jun;
11(10):2620-2637.
PMID: 34078620
Reduced protein levels of SMARCB1 (also known as BAF47, INI1, SNF5) have long been observed in synovial sarcoma. Here, we show that combined genetic loss with expression in mice synergized...
6.
Menz B, Johnson J, Gillard D, Chong W, Ward M
J Pharm Pract
. 2021 May;
34(3):386-396.
PMID: 33969772
Background: Immune checkpoint inhibitors (ICIs) are an emerging treatment in cancer therapy for prolonging life, minimizing symptoms, and selectively targeting cancer. Program death 1 (PD-1) inhibitors, such as nivolumab, fall...
7.
Reuter S, Schultz H, Ward M, Grant C, Paech G, Banks S, et al.
Br J Clin Pharmacol
. 2021 Apr;
87(11):4461-4466.
PMID: 33852164
The consumption of caffeine has been linked to osteoporosis, believed to be due to enhanced bone resorption as a result of increased calcium excretion in the urine. However, the amount...
8.
Salah H, Stivers N, Jarboe E, Dodson M, Ward M
Int J Gynecol Pathol
. 2020 Oct;
40(5):470-476.
PMID: 33075019
Extraskeletal myxoid chondrosarcoma of the vulva is a very rare tumor, with less than 10 cases reported in the literature. We report a case of a 45-yr-old woman with extraskeletal...
9.
Petito E, Foster D, Ward M, Sykes M
Curr Top Med Chem
. 2018 Dec;
18(26):2230-2238.
PMID: 30569859
Poor profiles of potential drug candidates, including pharmacokinetic properties, have been acknowledged as a significant hindrance to the development of modern therapeutics. Contemporary drug discovery and development would be incomplete...
10.
Reuter S, Evans A, Ward M
CPT Pharmacometrics Syst Pharmacol
. 2018 Nov;
8(1):26-33.
PMID: 30426719
Palivizumab for respiratory syncytial virus (RSV) immunoprophylaxis in premature infants poses a significant economic challenge. Although standard dosing of palivizumab results in unnecessary drug accumulation without additional clinical benefit, some...